OncRef

Clinical Trial: NCT05325632

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Status:

RECRUITING

Phase:

Phase 2

Lead Sponsor:H. Lee Moffitt Cancer Center and Research Institute
Information Provided By:H. Lee Moffitt Cancer Center and Research Institute
Last Update Posted:2026-03-02

Study Overview

Brief Summary

The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help people with HER2 (human epidermal growth factor receptor 2) positive breast cancer.

Official Title

A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed Dendritic Cell (DC1) Vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer

Conditions

HER2-positive Breast Cancer

Intervention / Treatment

  • Biological: HER-2 pulsed DC1
  • Drug: Trastuzumab
  • Drug: Pertuzumab
  • Drug: Paclitaxel
  • Procedure: Resection surgery

Other Study ID Numbers

  • MCC-20915

Start Date (Actual)

2021-10-28

Primary Completion Date (Estimated)

2027-02

Study Completion Date (Estimated)

2027-09

Enrollment (Estimated)

53

Study Type

Interventional

Phase

Phase 2